Sarilumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sarilumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
80
Registered trials
87
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sarilumab can convert its Monoclonal antibody profile and IL-6RA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sarilumab (query alias: sarilumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-6RA; IL-6RA antagonists |
| Highest global status | Approved |
| Originator | Sanofi |
| Active developers | Regeneron Pharmaceuticals, Inc., Sanofi Winthrop Industrie SA, Sanofi |
The MCP disease footprint includes Polyarticular Juvenile Idiopathic Arthritis, Polymyalgia Rheumatica, Rheumatoid Arthritis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07286214 | Phase 4 | Recruiting | 300 | Sustained remission at Week 52 (yes/no) in participants with early relapsing polymyalgia rheumatica (PMR) who received sarilumab 200 mg q2w with 52-week prednisone taper |
| NCT07154290 | Phase 2 | Recruiting | 300 | Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| NCT07196306 | Phase 2 | Withdrawn | Not disclosed | Time to clinical outcome improvement |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
EFFICACY AND SAFETY OF INTERLEUKIN-6 RECEPTOR INHIBITORS IN GIANT CELL ARTERITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Not Applicable; n=364; evaluation: Positive. Reported fields: SAE: RR = 0.92, P-Value = 0.75; SAE: RR = 0.92, P-Value = 0.75
EARLY USE OF SARILUMAB IN PATIENTS WITH GLUCOCORTICOID-RESISTANT PMR IMPROVES OUTCOMES ─ INSIGHTS FROM RANDOMIZED CONTROLLED TRIAL AND REAL-WORLD DATA
Phase 3; n=118; evaluation: Positive. Reported fields: SR = 18.0 % ; SR = 36.0 % ; SR = 20.0 %
NON-STANDARD TREATMENTS USE IN GIANT CELL ARTERITIS: DATA FROM THE LARGE VESSEL VASCULITIS FRENCH STUDY GROUP
Not Applicable; n=47; evaluation: Positive. Reported fields: AE(discontinuation) = infectious colitis on secukinumab, diverticular-associated pancolitis, severe neutropenia on sarilumab, and interstitial lung disease on tofacitinib. % ; AE(discontinuation) = 19.6 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sarilumab addresses Polyarticular Juvenile Idiopathic Arthritis, Polymyalgia Rheumatica, Rheumatoid Arthritis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2017-12-08 | Sanofi and Asahi Kasei Pharma enter license agreement for marketing of Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan | Approved | Financial terms not disclosed |
| 2007-11-29 | Regeneron initiates major global collaboration with Sanofi-aventis to develop and commercialize fully-human therapeutic antibodies | Discovery | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
